Translational initiatives in thrombolytic therapy
ME Klegerman - Frontiers of medicine, 2017 - Springer
Once thrombi have formed as part of the pathology defining myocardial infarction, ischemic
stroke, peripheral arterial disease, deep venous thrombosis or other embolic disorders, the …
stroke, peripheral arterial disease, deep venous thrombosis or other embolic disorders, the …
Novel or expanding current targets in fibrinolysis
T Wyseure, PJ Declerck - Drug discovery today, 2014 - Elsevier
Highlights•Despite the availability of revascularization strategies the care of heart disease
and stroke patients remains challenging.•There is an unmet clinical need to explore novel …
and stroke patients remains challenging.•There is an unmet clinical need to explore novel …
Novel and emerging therapies: thrombus-targeted fibrinolysis
Thrombolytic therapy by infusion of analogs of tissue plasminogen activator (tPA), other
recombinant-based plasminogen activators (eg, alteplase, reteplase, and tenecteplase) …
recombinant-based plasminogen activators (eg, alteplase, reteplase, and tenecteplase) …
Hidden potential of highly efficient and widely accessible thrombolytic staphylokinase
Stroke burden is substantially increasing but current therapeutic drugs are still far from ideal.
Here we highlight the vast potential of staphylokinase as an efficient, fibrin-selective …
Here we highlight the vast potential of staphylokinase as an efficient, fibrin-selective …
Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion
Vascular occlusion is one of the major causes of mortality and morbidity. Blood vessel
blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep …
blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep …
Novel approaches to thrombolysis based on modulation of endogenous fibrinolysis
S Stefansson, DA Lawrence, T Herren… - Coronary artery …, 1998 - journals.lww.com
Improvements may be realized as a result of increased efficacy, greater safety or reduced
cost. One approach to increasing the efficacy of thrombolytic therapy has been the …
cost. One approach to increasing the efficacy of thrombolytic therapy has been the …
[引用][C] Engineered staphylokinase variants with reduced immunogenicity
D Collen - Fibrinolysis and Proteolysis, 1998 - Elsevier
Acute myocardial infarction and ischemic stroke are the two main causes of death and
disability in our Western societies. Thrombolytic therapy of these diseases is based on the …
disability in our Western societies. Thrombolytic therapy of these diseases is based on the …
Thrombolytic agents: nanocarriers in controlled release
Thrombosis is a life‐threatening pathological condition in which blood clots form in blood
vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes …
vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes …
Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches
RL Medcalf - Current Drug Targets, 2011 - ingentaconnect.com
The plasminogen activating enzyme system has been exploited and harnessed for
therapeutic, mainly thrombolytic benefit for many years. While plasminogen activator-based …
therapeutic, mainly thrombolytic benefit for many years. While plasminogen activator-based …
Exploitation of fibrinolytic enzymes in combating blood clotting disorders–recent advances and strategies: A comprehensive Review
SK Sahoo, S Sahoo - Advances in Pharmaceutical Biotechnology: Recent …, 2020 - Springer
Formation of blood clumps inside vessels which restrict blood circulation throughout
circulatory system is known as thrombosis. This leads to origin of numerous abnormalities …
circulatory system is known as thrombosis. This leads to origin of numerous abnormalities …